Screener Summaries Updates Institutions Sign In More Updates › Other Events › AXSM Other Events · Jul 15, 2026
On July 15, 2026, the U.S. Food and Drug Administration accepted for filing the New Drug Application for AXS-12… AXSM Axsome Therapeutics, Inc.
On July 15, 2026, the U.S. Food and Drug Administration accepted for filing the New Drug Application for AXS-12 (reboxetine) to treat cataplexy in patients with narcolepsy. Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders.
More from Axsome Therapeutics, Inc. Reports $259.7M Q3 revenue, up 52% year-over-year Nov 2, 2026 Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a… Aug 10, 2026 On June 5, 2026, Axsome Therapeutics adopted an Executive Severance and Change in Control Plan Jun 9, 2026 At the 2026 Annual Meeting of Stockholders held on June 5, 2026, Axsome Therapeutics, Inc. stockholders elected Mark… Jun 9, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
